Are Prescription Obesity Drug Companies Permanently Broken? Print E-mail
By Brian Wilson - Lead Contributor   
Thursday, 22 May 2014 07:49
Yesterday we discussed the sheer extent of the recent selloff in biotech, and the buying opportunities that are available once again.
Read more...
 
Three biotechs with positive institutional transactions, strong price to cash ratios and "buy" recommendations from analysts Print E-mail
By A. Deniken   
Thursday, 22 May 2014 04:18
The names of big-board biotechnology listed firms IsoRay, Inc. (NYSE MKT: ISR), CEL-SCI Corporation (NYSE MKT: CVM), and Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), came up after we set out to find low priced biotech stocks with market caps in the $50m to $300m range which, based on a fixed set of fundamental and technical criteria, might be hinting at bullish investment trade sentiments.
Read more...
 
It's Time To Accumulate Crashed Biotechs Like ISIS Print E-mail
By Brian Wilson - Lead Contributor   
Wednesday, 21 May 2014 07:47
After a well-deserved selloff in the biotech space, we are much more comfortable with the pricing of most of the NASDAQ-traded biotech stocks that we follow.
Read more...
 
Aegerion's "HoFH Empire" Is Crumbling Fast Print E-mail
By Brian Wilson - Lead Contributor   
Tuesday, 20 May 2014 07:44
Last year, Aegerion was positioning itself to utterly dominate the drug market for a rare genetic disease known as Homozygous Familial Hypercholesterolemia (HoFH) with its newly approved drug Juxtapid (lomitapide).
Read more...
 
A Disturbing Lack of Information From Northwest Bio's DCVax Ph2 Trial Print E-mail
By Brian Wilson - Lead Contributor   
Sunday, 18 May 2014 23:39
Last week, the cancer immunotherapy company Northwest Biotherapeutics (NWBO) issued a press release discussing a case study from their Phase II trial for DCVax-Direct in the treatment of solid tumors.
Read more...
 
CEL-SCI's Insider Warrant Buy; May Underscore Value of Shares Print E-mail
By David Ibrahim   
Tuesday, 08 April 2014 03:41
icon_insiderbuysChief Executive Officer, Geert Kersten of Phase III drug developer CEL-SCI (AMEX:CVM)  made a notable insider purchase of 170,000 Series S Warrants confirmed by a Form 4 filing reported on Monday with the Securities and Exchange Commission.
Read more...
 
3 Small Cap Biotechs With Near-Term Catalysts Print E-mail
By Scott Matusow   
Thursday, 06 March 2014 10:17
Synthetic Biologics (SYN) expects to present top-line data from its Trimesta/Copaxone combo Phase II multi-center clinical trial involving 164 women for the treatment of relapsing-remitting multiple sclerosis (MS) in women.
Read more...
 
Xenoport Gaining Momentum, Could It Be The Next Small Cap Biotech Flyer Print E-mail
By Scott Matusow   
Tuesday, 25 February 2014 08:16
Xenoport (XNPT) focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological disorders.
Read more...
 
Synthetic Biologics Under The Radar With Upcoming Multiple Sclerosis Data Catalyst Print E-mail
By Scott Matusow   
Thursday, 20 February 2014 08:29
Similar to how a blue-chip company might have an increase in stock price before an earnings call, small-cap developmental biotechs often increase in price before important clinical data releases, Advisory Committee Meetings (ADCOM), and U.S. Food and Drug Administration (FDA) drug approvals.
Read more...
 
Significant Upcoming Catalysts For These Biotechs Should Provide Opportunity Print E-mail
By Scott Matusow   
Friday, 14 February 2014 08:48
This week we want to highlight several biotechs with catalysts coming up in the near future. These price driving catalysts may include FDA approval decisions, FDA Advisory Committee (ADCOM) recommendations, product launches, and clinical data releases.
Read more...
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 14 of 56

Newsletter